Drug profile · INN
eribulin mesilate
HALAVEN INITIAL APPROVAL
eribulin mesilate (HALAVEN INITIAL APPROVAL) is a tubulin inhibitor.
PMDA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — eribulin mesilate
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.78
Quick answer
eribulin mesilate (HALAVEN INITIAL APPROVAL) is a tubulin inhibitor.
Key facts
INN eribulin mesilate
Brand HALAVEN INITIAL APPROVAL
Mechanism Tubulin inhibitor
Target Tubulin
Mechanism of action
Tubulin inhibitor
Primary target: Tubulin
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is eribulin mesilate?
eribulin mesilate (HALAVEN INITIAL APPROVAL) is a tubulin inhibitor.
What is the brand name for eribulin mesilate?
HALAVEN INITIAL APPROVAL is a marketed brand name for eribulin mesilate. Check FDA Drugs@FDA for the current US label holder and prescribing information.